Saxagliptin prevents vascular remodeling and oxidative stress in db/db mice. Role of endothelial nitric oxide synthase uncoupling and cyclooxygenase

Vascular Pharmacology

Volumn 76, Issue , 2015, Pages 62-71

  Solini, Anna ^a   Rossi, Chiara ^a   Duranti, Emiliano ^a   Taddei, Stefano ^a   Natali, Andrea ^a   Virdis, Agostino ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

COX; DPP IV inhibitors; Endothelium; Microcirculation; Oxidative stress

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; ACETYLCHOLINE; APOCYNIN; CYCLOOXYGENASE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROETHIDINE; METFORMIN; N(G) NITROARGININE METHYL ESTER; PROSTAGLANDIN SYNTHASE; SAXAGLIPTIN; SUPEROXIDE; THROMBOXANE A2 RECEPTOR; ADAMANTANE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDE; HYDRAZINE DERIVATIVE; NITRIC OXIDE; NOS3 PROTEIN, MOUSE; PYRAZOLE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; BLOOD VESSEL REACTIVITY; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DB/DB MOUSE; DOWN REGULATION; ENDOTHELIAL DYSFUNCTION; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULAR REMODELING; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; MESENTERIC ARTERY; METABOLISM; VASCULAR ENDOTHELIUM; VASODILATATION;

ADAMANTANE; ANIMALS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; ENDOTHELIUM, VASCULAR; HYDRAZINES; MALE; MESENTERIC ARTERIES; MICE; MICE, INBRED C57BL; NADPH OXIDASE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; PYRAZOLES; VASCULAR REMODELING; VASODILATION;

EID: 84961161310     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2015.10.002     Document Type: Article

References (40)

1. E. Agabiti Rosei, D. Rizzoni, Small artery remodelling in diabetes, J. Cell.Mol.Med. 14 (2010) 1030-1036.
2. D.H. Endemann, Q. Pu, C. De Ciuceis, et al., Persistent remodeling of resistance arteries in type 2 diabetic patients on antihypertensive treatment, Hypertension 43 (2004) 399-404.
3. D. Rizzoni, E. Porteri, D. Guelfi, et al., Endothelial dysfunction in small resistance arteries of patients with non-insulin-dependent diabetes mellitus, J. Hypertens. 19 (2001) 913-919.
4. L. Gao, G.E. Mann, Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signalling, Cardiovasc. Res. 82 (2009) 9-20.
5. M. Feletou, Y. Huang, P.M. Vanhoutte, Endothelium-mediated control of vascular tone: COX-1 and COX-2 products, Br. J. Pharmacol. 164 (2011) 894-912.
6. Z. Bagi, N. Erdei, A. Toth, et al., Type 2 diabetic mice have increased arteriolar tone and blood pressure: enhanced release of COX-2-derived constrictor prostaglandins, Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1610-1616.
7. A.J. Flammer, T. Anderson, D.S. Celermajer, et al., The assessment of endothelial function: from research into clinical practice, Circulation 126 (2012) 753-767.
8. D. Rizzoni, E. Porteri, G.E. Boari, et al., Prognostic significance of small-artery structure in hypertension, Circulation 108 (2003) 2230-2235.
9. C.F. Deacon, J.J. Holst, Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety, Expert. Opin. Pharmacother. 14 (2013) 2047-2058.
10. D. Reinhold, T. Kahne, A. Steinbrecher, et al., The role of dipeptidyl peptidase IV (DP IV) enzymatic activity in T cell activation and autoimmunity, Biol. Chem. 383 (2002) 1133-1138.
11. V. Matheeussen, L. Baerts, G. De Meyer, et al., Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries, Biol. Chem. 392 (2011) 189-198.
12. M.R. Rizzo, M. Barbieri, R. Marfella, et al., Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition, Diabetes Care 35 (2012) 2076-2082.
13. M. Barbieri, M.R. Rizzo, R. Marfella, et al., Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPPIV inhibitors, Atherosclerosis 227 (2013) 349-354.
14. R.P. Mason, R.F. Jacob, R. Kubant, et al., Effect of enhanced glycemic control with saxagliptin on endothelial nitric oxide release and CD40 levels in obese rats, J. Atheroscler. Thromb. 18 (2011) 774-783.
15. R.P. Mason, R.F. Jacob, R. Kubant, et al., Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive rats, J. Cardiovasc. Pharmacol. 60 (2012) 467-473.
16. M. Ayaori, N. Iwakami, H. Uto-Kondo, et al., Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients, J. Am. Heart. Assoc. 28 (2013), e003277.
17. A. Virdis, R. Colucci, M. Fornai, et al., Cyclooxygenase-2 inhibition improves vascular endothelial dysfunction in a rat model of endotoxic shock: role of inducible nitricoxide synthase and oxidative stress, J. Pharmacol. Exp. Ther. 312 (2005) 945-953.
18. A. Virdis, R. Colucci, M. Fornai, et al., Cyclooxygenase-1 is involved in endothelial dysfunction of mesenteric small arteries from angiotensin II-infused mice, Hypertension 49 (2007) 679-686.
19. A. Virdis, R. Colucci, M.F. Neves, et al., Resistance artery mechanics and composition in angiotensin II-infused mice: effects of cyclooxygenase-1 inhibition, Eur. Heart J. 33 (2012) 2225-2234.
20. K.R. Kim, S.D. Rhee, H.Y. Kim, et al., KR-62436, 6-(2-[2-(5-cyano-4, 5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino)nicotinonitrile, is a novel dipeptidyl peptidase-IV (DPP-IV) inhibitor with anti-hyperglycemic activity, Eur. J. Pharmacol. 518 (2005) 63-70.
21. A. Virdis, F. Santini, R. Colucci, et al., Vascular generation of tumor necrosis factoralpha reduces nitric oxide availability in small arteries from visceral fat of obese patients, J. Am. Coll. Cardiol. 58 (2011) 238-247.
22. M. Pannirselvam, W.B. Wiehler, T. Anderson, et al., Enhanced vascular reactivity of small mesenteric arteries from diabetic mice is associated with enhanced oxidative stress and cyclooxygenase products, Br. J. Pharmacol. 144 (2005) 953-960.
23. M.F. Neves, A. Virdis, E.L. Schiffrin, Resistance artery mechanics and composition in angiotensin II-infused rats: effects of aldosterone antagonism, J. Hypertens. 21 (2003) 189-198.
24. P. Brassard, F. Amiri, E.L. Schiffrin, Combined angiotensin II type 1 and type 2 receptor blockade on vascular remodeling and matrix metalloproteinases in resistance arteries, Hypertension 46 (2005) 598-606.
25. A. Kelly-Cobbs, M.M. Elgebaly, W. Li, et al., Pressure-independent cerebrovascular remodelling and changes in myogenic reactivity in diabetic Goto-Kakizaki rat in response to glycaemic control, Acta Physiol (Oxf.) 203 (2011) 245-251.
26. M. Abdelsaid, J. Kaczmarek, M. Coucha, et al., Dual endothelin receptor antagonism with bosentan reverses established vascular remodeling and dysfunctional angiogenesis in diabetic rats: relevance to glycemic control, Life Sci. 118 (2014) 268-273.
27. S. Kroller-Schon, M. Knorr, M. Hausding, et al., Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition, Cardiovasc. Res. 96 (2012) 140-149.
28. K. Ban, M.H. Noyan-Ashraf, J. Hoefer, et al., Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and-independent pathways, Circulation 117 (2008) 2340-2350.
29. A. Basu, N. Charkoudian, W. Schrage, et al., Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride, Am. J. Physiol. Endocrinol. Metab. 293 (2007), E1289-1295.
30. T. Nystrom, M.K. Gutniak, Q. Zhang, et al., Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease, Am. J. Physiol. Endocrinol. Metab. 287 (2004), E1209-1215.
31. J. Su, P.A. Lucchesi, R.A. Gonzalez-Villalobos, et al., Role of advanced glycation end products with oxidative stress in resistance artery dysfunction in type 2 diabetic mice, Arterioscler. Thromb. Vasc. Biol. 28 (2008) 1432-1438.
32. X.Y. Tian, W.T.Wong, A. Xu, et al., Rosuvastatin improves endothelial function in db/dbmice: role of angiotensin II type 1 receptors and oxidative stress, Br. J. Pharmacol. 164 (2011) 598-606.
33. U. Forstermann, T. Munzel, Endothelial nitric oxide synthase in vascular disease: from marvel to menace, Circulation 113 (2006) 1708-1714.
34. T.Munzel, T. Gori, R.M. Bruno, et al., Is oxidative stress a therapeutic target in cardiovascular disease? Eur. Heart. J. 31 (2010) 2741-2748.
35. C. Marchesi, T. Ebrahimian, O. Angulo, et al., Endothelial nitric oxide synthase uncoupling and perivascular adipose oxidative stress and inflammation contribute to vascular dysfunction in a rodent model of metabolic syndrome, Hypertension 54 (2009) 1384-1392.
36. A. Virdis, M.F. Neves, F. Amiri, et al., Role of NAD(P)H oxidase on vascular alterations in angiotensin II-infused mice, J. Hypertens. 22 (2004) 535-542.
37. A. Virdis, R. Colucci, D. Versari, et al., Atorvastatin prevents endothelial dysfunction inmesenteric arteries from spontaneously hypertensive rats: role of cyclooxigenase 2-derived contracting prostanoids, Hypertension 53 (2009) 1008-1016.
38. C. Schurmann, A. Linke, K. Engelmann-Pilger, et al., The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice, J. Pharmacol. Exp. Ther. 342 (2012) 71-80.
39. Y. Ye, K.T. Keyes, C. Zhang, et al., The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA, Am. J. Physiol. Heart. Circ. Physiol. 298 (2010), H1454-1465.
40. C.F. Liang, J.T. Liu, Y. Wang, et al., Toll-like receptor 4 mutation protects obese mice against endothelial dysfunction by decreasing NADPH oxidase isoforms 1 and 4, Arterioscler. Thromb. Vasc. Biol. 33 (2013) 777-784.